Regulatory submissions for AMT-130 in Huntington's disease are on track for Q3 2026, with pivotal data expected in September. Strong cash position of $810.3 million supports operations into 2030, while pipeline programs show promising early results and manageable safety profiles.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.